These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Dynamic monitoring of plasma Epstein-Barr Virus DNA load can predict the occurrence of lymphoproliferative disorders after haploidentical hematopoietic stem cell transplantation]. Chen J, Sun YQ, Xu LP, Zhang XH, Liu KY, Mo XD, Cheng YF, Huang XJ, Wang Y. Zhonghua Xue Ye Xue Za Zhi; 2023 Apr 14; 44(4):284-288. PubMed ID: 37356996 [Abstract] [Full Text] [Related]
7. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA, Kraft GH, Mayes MD, McDonagh KT, Chen CS, Dipersio J, Lemaistre CF, Pavletic S, Sullivan KM, Sunderhaus J, Furst DE, McSweeney PA. Biol Blood Marrow Transplant; 2003 Sep 14; 9(9):583-91. PubMed ID: 14506660 [Abstract] [Full Text] [Related]
8. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients. Patel C, Pasciolla M, Abramova R, Salerno D, Gomez-Arteaga A, Shore TB, Orfali N, Mayer S, Hsu J, Phillips AA, Chaekal OK, Satlin MJ, Soave R, Kodiyanplakkal RPL, Drelick A, Plate M, Besien KV. Transplant Cell Ther; 2023 Feb 14; 29(2):132.e1-132.e5. PubMed ID: 36334653 [Abstract] [Full Text] [Related]
10. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation. Kim BK, Kang HJ, Hong KT, An HY, Choi JY, Lee JS, Park SS, Shin HY. Transpl Infect Dis; 2019 Dec 14; 21(6):e13182. PubMed ID: 31556214 [Abstract] [Full Text] [Related]